simultaneously identified antibodies suggests that peritransfusion factors are important determinants of alloantibody detectability and duration. We also find some evidence that detection durations for sequentially identified antibodies are also more highly correlated than those for randomly selected antibodies across all patients, suggesting that patient-specific factors also play a role in determining alloantibody persistence. P atients exposed to foreign red blood cell (RBC) antigens after blood transfusion, transplantation, or during pregnancy are at risk of developing alloantibodies. These alloantibodies can cause serious adverse transfusion reactions if the patient is reexposed to the same RBC antigen. It is therefore critical to prevent reexposure by selecting compatible blood products in subsequent transfusions. Once an alloantibody has been identified, a patient should always receive blood crossmatched for the corresponding antigen, even if the alloantibody becomes undetectable. This requirement adds significant burden to the transfusion process.
Alloimmunization is not uncommon as 1% to 10% of the general transfused population develop one or more alloantibodies. [1] [2] [3] [4] [5] Surprisingly the rate of alloimmunization is not completely related to antigen exposure. Some patients appear more susceptible to alloantibodies than others. 3, 6 However, the genetic and/or environmental factors controlling the susceptibility to alloimmunization remain unknown, and to date, the putative population of responders cannot be identified a priori. Once identified, alloantibodies can be detected for periods ranging from a few days to a decade. [7] [8] [9] [10] [11] Previous investigators have estimated that the majority of the antibodies become undetectable within 1 year. 11 This period is shorter than what is generally observed after adult vaccination which can last for several years even without secondary immunization including smallpox and yellow fever. 12, 13 The reasons for such variability in the detection duration are not understood. Antibody specificities have been shown to play a role in a few instances (e.g., anti-D appear more persistent than anti-Jka), 11 but the underlying mechanisms remain elusive, and other factors warrant investigation. For instance, it is not known if the conditions at the time of transfusion influence the antibody titers in the long term or if patient-specific factors that persist across transfusions also play a role. To investigate these questions, we performed a retrospective analysis of blood bank clinical records and studied the variability in alloantibody detection duration in patients with multiple antibodies. Patients with multiple antibodies can be seen as a population that is highly susceptible to alloimmunization and offer an opportunity to study the factors controlling the persistence of alloantibodies. Within a patient, we can evaluate the detection duration of antibodies that have been discovered simultaneously (antibodies discovered on the same screen) and compare it to the detection duration of those discovered sequentially (one antibody first detected before another one by distinct antibody screens). If conditions at the time of transfusion control the antibody titer in the long term, the detection duration of simultaneous antibodies should be more positively correlated than the detection duration of antibodies developed at different times. On the other hand, if patient-specific factors that are less likely to vary from one transfusion to the next are more important, then the timing of alloimmunization events should not be critical, and the withinpatient variability in the detection duration should be similar in patients with antibodies discovered sequentially and simultaneously. The situation may be more complicated, and the dominant factors may vary from transfusion to transfusion or from patient to patient. By comparing the variability in detection duration within patients, we can begin to investigate these possible mechanisms of alloimmunization.
MATERIALS AND METHODS

Patient selection
We retrospectively studied patients from the Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) expressing at least one alloantibody between 2008 and 2015. Similarly to others, we classified antibodies based on the result of the first antibody screen. 11 Antibodies detected in the patient's first screen at the hospital were called "existing" whereas antibodies identified subsequently (i.e., after at least one negative screen with no previous history and thus more likely to reflect a primary immune response) were listed as "newly developed."
Estimation of the detection duration
The exact date on which an antibody titer becomes too low to be detected (evanescence date) is unknown because antibody screens are typically done very infrequently. 14 To overcome this uncertainty, we estimated the detection duration using three different definitions: the minimum duration (duration between the first and last positive screen), the maximum duration (duration between the first positive screen and the first subsequent negative screen), and the mid-duration (average between the minimum and maximum durations; see Fig. 1 ). It is difficult to evaluate the superiority of one estimator over the others, and the analyses were therefore performed using each of the three estimators. This article shows the results based on the mid-duration. The results based on the minimum Fig. 1 . Estimation of antibody (ab) detection duration. Antibody detection duration is not known precisely and must be estimated. Three different estimation strategies could be used: the minimum duration (duration between the first and last positive screen), the maximum duration (duration between the first positive screen and the first subsequent negative screen), and the mid-duration (average between the minimum and maximum durations). Throughout this study, we chose to focus on the mid-duration. Calculations were also performed on the minimum and maximum durations and in general yielded qualitatively similar conclusions (see supplementary information).
and maximum durations are included in supplementary information (available as supporting information in the online version of this paper For BWH, antibody screens were performed on a fully automated blood bank analyzer (Tango, Bio-Rad; solidphase method), and antibody identification was done with PEG enhancement (manual tube method). For MGH, blood was preserved in Adsol. During the period of study, approximately 50% of the RBCs transfused were leukoreduced. For BWH, the majority of the units were leukoreduced, and all the RBCs were irradiated. Units were usually collected in AS-1 or AS-3, but some units did not have any ASs, just anticoagulant (CPD or CPDA-1).
Within-patient variability in alloantibody detection duration
Antibodies developed in a patient may be detected for various periods of time. This section describes two approaches or metrics used to quantify this within-patient variability in detection duration. These metrics were used to test if patient-specific and/or peritransfusion factors control alloantibody detectability.
The first approach was based on the maximum difference in detection duration within each patient (MaxDiff). The maximum difference is simply the difference in detection duration between the shortest-lived and longest-lived antibodies within a patient. For instance, if a patient has three antibodies detected for d ab1 5 15 days, d ab2 5 20 days, and d ab3 5 100 days, the largest difference for that patient is MaxDiff 5 85 days.
The second approach to quantifying the withinpatient variability used the standard deviation (SD) of detection durations (SD 5
where n is the total number of antibodies within a patient, and d is the mean detection duration for that patient).
These metrics (MaxDiff and SD) were calculated for each patient. The means of MaxDiff and SD in the groups of patients with antibodies identified simultaneously and sequentially were then calculated. If peritransfusion factors control the detection duration, antibodies developed at the same time should behave in a more similar way. In other words, the means of MaxDiff and SD should be lower in the group of patients with multiple antibodies discovered simultaneously compared to the group with antibodies identified sequentially.
To test the importance of patient-specific factors, we simulated a virtual population of 10,000 patients with multiple antibodies. For each virtual patient, the detection duration of the antibodies was randomly selected using the observed distribution of detection durations. This stochastic selection simulated a virtual patient who was not affected by any patient-specific or transfusion-specific effects. The mean MaxDiff and SD in the virtual population were calculated and compared to our clinical observations.
Statistical analysis
Means across groups were compared using the t test or the Mann-Whitney test. Proportions between two groups were compared using Z scores. The Mann-Whitney test was used to compare the number of transfusions and the detection duration of antibodies across groups because these variables are highly skewed. Kaplan-Meier analysis was used to estimate the time to evanescence. Survival curves were compared using the log rank test. All the analyses were performed in computer software (MATLAB 2016a, MathWorks).
RESULTS
To study the detection duration of antibodies in patients with multiple antibodies, several filters were applied to our database. The filters are based on antibody characteristics (number of screens before and after the first identification) and on the patient characteristics (number of antibodies per patient). We start by describing the general characteristics of our cohort. We then report our investigation of whether the number of antibodies discovered in a patient (single or multiple) and sequence of events impacted the detectability. In particular, we compared the fate and detection duration of alloantibodies within patients.
Antibody and patient characteristics
A total of 9222 alloantibodies in 6590 patients were identified (mean, approx. 1.4 antibodies per patient). Our population was 69% women, and the mean age was 61 years. The cohort included 79% Caucasian, 8% African American, 5% Hispanic, and 3% Asian. On average, alloantibodies developed after 3.4 transfusions at the study hospitals (SD, 10.3; median, 1 month), and patients were followed for 7.8 months (SD, 14.4; median, 0.4 months) after the first identification. The most frequent antibody specificities were anti-E (n 5 2014 patients), anti-K (n 5 1576), anti-D (n 5 968), and anti-C (n 5 606; details in Table 1 ). Twenty-seven percent of the patients developed two or more antibodies (n 5 4412 antibodies, n 5 1780 patients).
The most frequent pairs of antibodies were C-D (n 5 356), E-K (n 5 244 patients), and c-E (n 5 230). In the subsequent gender-specific analysis, anti-D detected in women were excluded as this antibody specificity is often related to pregnancy.
To compare the detection durations of antibodies, we restricted analysis to antibodies 1) discovered after at least one negative screen and 2) tested at least once after the first identification. This filter also allowed us to determine whether two antibodies were developed sequentially or simultaneously. A total of 2129 antibodies in 1429 patients were identified. A total of 990 patients had a single antibody, and 439 had two or more antibodies satisfying our criteria. Among the 439 patients with multiple antibodies, 141 had exclusively sequential antibodies, 217 patients had exclusively simultaneous antibodies, and 81 had both sequential and simultaneous antibodies. The proportion of female patients and the mean age were similar across the groups (Table 2) .
Antibody characteristics are similar for singly and multiply alloimmunized patients
The rate of evanescence was slightly higher in patients with a single antibody (63%) compared with patients with multiple antibodies (59%, p 5 0.05; see Table 2 ). Among the evanescent antibodies, the first negative test after discovery (maximum detection duration; see Fig. 1 for the various definitions of detection duration) occurred after around 6 to 7 months in both groups (p > 0.05). Thus, the basic characteristics of the antibodies in the multiply alloimmunized patients seem comparable to those in the singly alloimmunized, but within the group of patients with multiple antibodies, there was heterogeneity between sequential versus simultaneous antibodies as discussed next.
Sequential and simultaneous antibody pair characteristics
We investigated the detection period of antibodies in patients with single or multiple antibodies. Figure 2 shows first that the detection durations of single and sequential antibodies were not different (p > 0.17) and second that the detection duration of simultaneous antibodies was longest (p < 0.03). These results were observed in both men and women, suggesting that the differences in detection duration between sequential and simultaneous antibodies are not due to gender-specific effects. Similar results were obtained when the min-and the maxduration were used (see supplementary information). Two years after the initial identification, the estimated proportions of persistent antibodies in the three classes were similar (Fig. 2) .
Fate of antibodies discovered simultaneously
We next compared the fates of alloantibodies discovered simultaneously. Simultaneous antibodies were classified into three categories: 1) "all persistent" if the antibodies were consistently detected during every follow-up screen, 2) "all evanescent-same date" if all antibodies first became undetectable during the same screen, and 3) "different fates" if the antibodies had different detection durations, including the scenario where one antibody persisted while the other evanesced. A total of 298 patients developed two or more antibodies discovered simultaneously (724 antibodies in total). In 76% of these cases, the simultaneous antibodies were still persistent at the last screen or had become evanescent at the same screen. Among the antibodies that become evanescent, a majority (62% 5 122/(122 1 76)) became evanescent at the same screen. This pattern was found both in men and women (see Table 3 and supplementary information for more detail).
Detection duration of alloantibodies: within-patient variability
Antibodies identified together in the same antibody screen tended either to remain detectable or to become undetectable in the same subsequent antibody screen. This high concordance may be related to conditions at the time of transfusion but may also reflect some patient-specific effects: the detectability of antibodies may indeed be predetermined in each patient. To distinguish between these two explanations, we quantified and compared the variability in the duration of antibody detectability within patients. We calculated the maximum difference in detection duration within each patient (see definition of MaxDiff under Materials and Methods) using the three estimators of the detection duration. We then compared the results obtained in patients with sequential antibodies to those with simultaneous antibodies (Table 4) . We also quantified the expected difference if all antibody detection durations were pooled and sampled randomly, as would be expected if the duration of detectability were determined independently of any transfusion-specific or patient-specific factors (see "simulation" column in Table  4 and Materials and Methods). The within-patient variability in the detection duration was higher in the group with sequential antibodies (MaxDiff 5 108 days) compared to the group with simultaneous antibodies (MaxDiff 5 26 days, p < 10
24
). For simultaneous antibodies, the within-patient variability was lower than what is expected if the detection duration within a patient was a random process (200 days, p < 10
). The comparison of the within-patient variability between sequential antibodies and the random process was different when the calculations were based on the mid-or max-durations and not significant when the min-durations were used.
We also compared the standard deviation in detection durations within patients (see definition of SD under Materials and Methods). We calculated the detection duration standard deviation within each patient and then compared the mean SD of patients with sequential antibodies with the mean SD of patients with simultaneous antibodies. The mean SD in the sequential group was four ).
DISCUSSION
We investigated factors influencing the detection duration of RBC alloantibodies by studying patients with multiple antibodies. Our retrospective study revealed that 76% of antibodies identified together shared the same fate: they remained detectable for the duration of the follow-up period or became simultaneously undetectable in a subsequent antibody screen. Furthermore, we showed that within patients, the detection durations of multiple antibodies were more similar when the antibodies were developed together (mean difference, 26 days) than sequentially (mean difference, 108 days). This high concordance suggests that some unknown factors at the time of development of the antibodies help determine their eventual detectability. This impact is independent of the antibody specificity because in our cohort most of the simultaneous antibodies shared the same fate regardless of specificity. We refer to these unknown factors as "peritransfusion factors" because they seem to act around the time of each transfusion, as opposed to persisting in each patient across transfusions. This role for peritranfusion factors would imply that antibody titer at future times is partly determined during the early phase of B-cell activation and may be determined in a similar way for different antibody specificities. Potential candidate factors may relate to the immune or inflammatory state of the patient at the time of transfusion. Previous work in mouse models suggests that the inflammatory state at the time of transfusion influences the rate of alloimmunization and the strength of the immune response. [15] [16] [17] It seems plausible that the inflammatory state may also influence the detection duration. On average, simultaneously identified antibodies were detected for longer periods than antibodies discovered sequentially. The longer detection is consistent with a stronger immune response at the time of the transfusion that would generate higher initial titers for all the antibodies developed and hence longer and possibly more consistent detection durations. Follow-up study is required, and we cannot exclude the possibility that some patients may be more likely to develop simultaneous antibodies as well as longer-lived antibodies. In that case the detection duration would not be determined by the conditions at the time of transfusion factors but by patient-specific factors.
We also tried to assess the within-patient factors by comparing the detection durations in patients with multiple antibodies discovered sequentially with the variability expected if the duration is randomly determined. The comparison was different when based on the mid-or maxdurations but not significant when the min-durations were used. These results may suggest that patient-intrinsic factors are also relevant, leading to a higher intrapatient correlation in detectability duration than would be expected on average, but additional investigation is required.
Patients with single antibodies and those with multiple sequential antibodies had a similar pattern of detection durations. One might have expected that multiple alloimmunization events would reflect a more intense immune response leading to higher titers and longer detection. Whereas patients with prior RBC alloantibodies are known to form additional and sequential alloantibodies at a higher rate than those with no existing alloantibodies, 3, 6 the detection duration of these sequential antibodies was no different on average from that of the singletons. The similar detection durations observed in patients with single and multiple antibodies discovered sequentially may suggest that new alloimmunization events do not impact the titer of previously formed antibodies. We also note that a few patients with extremely high numbers of simultaneous antibodies also have very long persistence durations. While the small number of patients prevents generalization, these anecdotes are consistent with the idea that extreme factors present at the time of transfusion may have played a role in the extremely long persistence durations. This anecdotal pattern needs to be confirmed in larger data sets.
Our study is limited by its retrospective design, as previously noted. 6, 11, 18 The limitations include sporadic testing as well as lack of consistent follow-up, which may have a significant impact on antibody detectability. 14 As a result, and despite the fact that the analysis was restricted to antibodies that were discovered after at least one negative screen, we cannot guarantee that all the antibodies studied corresponded to a primary response. In the case of women, some antibodies were associated with pregnancy and not transfusion. The similar results found between men and women provide support for our conclusions and may also suggest either that the contribution of pregnancy to alloantibodies in our study is small or that analogous perialloimmunization factors act during pregnancy. Many studies have attempted to identify peritransfusion factors that influence risk of alloimmunization with no clear risk factors identified, and our study suggests that follow-up work investigating antibody detection duration as a function of peritransfusion conditions, including current diagnosis and recent clinical history, may be a complementary way to elucidate crucial immune mechanisms responsible for determining the persistence of immunity in general. Table S1 . Survival analysis of antibody persistence duration stratified by patient gender. The log-rank test was used to compare the survival curves obtained when the min-, mid and max-durations were applied. The table lists significance of the resulting p values: * p value < 0.05, ** p value < 0.01, *** p value < 0.001, or not significant (NS) if p value > 0.05. Analyses were performed in the full cohort, and separately in men and in women. The conclusions of the tests were similar for both genders and for the three estimators of the detectability duration. Table S2 . Variation in persistence duration withinpatients (MaxDiff ) calculated using the minimum persistence durations and the maximum persistence duration. The results are presented as mean 6 standard deviation (median). See Materials and Methods for more detail. Table S3 . Survival analysis of antibody persistence duration. Comparisons of the results of the log rank tests used to compare the survival curves obtained when the min-, mid-, and max-durations were used. Only antibodies directed against protein antigen were considered. Table S4 . Protein-antigen specific alloantibody multiplicity and pairwise evanescence patterns. Table S5 . Persistence durations of protein-antigenspecific alloantibodies. Fig. S1 . Comparison of the antibody detection duration in patients with a single antibody, and patients with sequential and simultaneous antibodies. Only antibodies directed against protein antigen were considered as described above.
